Compare Gilead Sciences, Inc. (GILD) vs Keel Infrastructure Corp. Common Stock (KEEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Keel Infrastructure Corp. Common Stock — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Keel Infrastructure Corp. Common Stock trades at $3.21 (market cap $2.06B). The key difference: Gilead Sciences, Inc. is far larger — about 88.4× Keel Infrastructure Corp. Common Stock's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Keel Infrastructure Corp. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Keel Infrastructure Corp. Common Stock for 0 Days on average.
| GILD | KEEL | |
|---|---|---|
Market Cap | $182.09B | $2.06B |
Volume | 4,960,247 | 26,532,713 |
Sector | Health | Technology |
52-Week High | $155.80 | $6.66 |
52-Week Low | $116.74 | $1.71 |
Typical Hold Time | 111 Days | 0 Days |
Enterprise Value | $205.15B | $2.38B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Keel Infrastructure Corp. Common Stock
Keel Infrastructure develops and owns digital and energy infrastructure for high-performance computing workloads. Its assets include data centers and power infrastructure that support AI computing.
Read more on KEEL →
